Cryoport, Worthington in Strategic Biostorage/Logistics Pact

Cryoport, Inc. has entered into a strategic partnership with Worthington Industries for the design and manufacture of biostorage and logistics equipment for use in Cryoport’s life sciences cryogenic logistics solutions. The partnership also expands Cryoport’s logistics areas such as storage and fulfillment.
 
Through its recently-acquired CryoScience by Taylor Wharton product line, Worthington manufactures cold chain storage and transport vessels and equipment that provide critically reliable transportation of biologics. Cryoport provides cold chain logistics solutions to protect frozen life sciences products from adverse thermal excursions during clinical development through commercial manufacture.
 
Jerrell Shelton, chief executive officer of Cryoport, said, “With the added competencies Worthington’s CryoScience by Taylor Wharton brings to Cryoport, we can concentrate on further advancing and expanding our cold chain solutions to meet the growing and varied demands for validated cryogenic logistics solutions in the life sciences market. With new, innovative, validated solutions enabled by Worthington, we are confident that our partnership will prove to be a great success in the marketplace for both parties.”
 
Andrew Pazahanick, vice president and general manger of Worthington’s CryoScience by Taylor-Wharton business added, “This strategic partnership between will help meet the quality and reliability demands of the growing life sciences industry. Cold chain logistics has become a strategic consideration, as there is an ever-increasing need for cryogenic logistics in the biopharma, animal health, cellular therapy and reproductive medicine markets. We are pleased to align our business with a key cryogenic logistics solution in the life sciences market that provides us immediate access to a distribution platform for our cryogenic products, equipment and services.”